Reuters logo
BRIEF-Ionis earns $75 mln from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx
February 14, 2017 / 12:42 PM / 9 months ago

BRIEF-Ionis earns $75 mln from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx

Feb 14 (Reuters) - Ionis Pharmaceuticals Inc -

* Ionis earns $75 million from Bayer for advancing IONIS-FXI Rx and IONIS-FXI-L Rx

* Co to also initiate development of IONIS-FXI-L(Rx), which uses Ionis’ proprietary ligand conjugated antisense, or LICA, technology Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below